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Abstract
Background: The antibody response generated during malaria infections is of particular interest, since the production of
specific IgG antibodies is required for acquisition of clinical immunity. However, variations in antibody responses could
result from genetic polymorphism of the HLA class II genes. Given the increasing focus on the development of subunit
vaccines, studies of the influence of class II alleles on the immune response in ethnically diverse populations is important,
prior to the implementation of vaccine trials.
Methods and Findings: In this study, we evaluated the influence of HLA-DRB1* and -DQB1* allelic groups on the naturally
acquired humoral response from Brazilian Amazon individuals (n=276) against P. vivax Merozoite Surface Protein-1 (MSP-1),
MSP-3a and MSP-9 recombinant proteins. Our results provide information concerning these three P. vivax antigens, relevant
for their role as immunogenic surface proteins and vaccine candidates. Firstly, the studied population was heterogeneous
presenting 13 HLA-DRB1* and 5 DQB1* allelic groups with a higher frequency of HLA-DRB1*04 and HLA-DQB1*03. The
proteins studied were broadly immunogenic in a naturally exposed population with high frequency of IgG antibodies
against PvMSP1-19 (86.7%), PvMSP-3 (77%) and PvMSP-9 (76%). Moreover, HLA-DRB1*04 and HLA-DQB1*03 alleles were
associated with a higher frequency of IgG immune responses against five out of nine antigens tested, while HLA-DRB1*01
was associated with a high frequency of non-responders to repetitive regions of PvMSP-9, and the DRB1*16 allelic group
with the low frequency of responders to PvMSP3 full length recombinant protein.
Conclusions: HLA-DRB1*04 alleles were associated with high frequency of antibody responses to five out of nine
recombinant proteins tested in Rondonia State, Brazil. These features could increase the success rate of future clinical trials
based on these vaccine candidates.
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Introduction
Malaria is one of the most prevalent parasitic diseases in tropical
and subtropical countries. About 500 million new cases are
reported annually, and it is estimated that around 1–2 million of
these cases are fatal [1]. Plasmodium vivax is the most widespread
malaria species affecting mainly Asian, South and Central
American countries, and the second leading cause of malaria,
responsible for 132–391 million infections per year [2].
Vaccination is considered one of the most promising strategies
for controlling this disease [3], however Plasmodium species have
a complex life cycle involving a mosquito vector and a vertebrate
host [4]. During asexual stage development merozoite surface
proteins and proteins released from the apical organelles
(rhoptries, micronemes, and dense granules) are responsible for
the cascade of events involved in the parasite invasion of red blood
cells (RBCs) [5]. In this context, the family of merozoite surface
proteins (MSPs) seems to be important for the first contact
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36419between merozoites and RBCs and they have therefore become
important targets for vaccine development [6,7,8,9]. In P. vivax,
the merozoite surface proteins (MSPs) PvMSP-1[10], the PvMSP-
3 family [11,12] and PvMSP-9 [13,14] are currently recognized as
vaccine candidates. The potential of these proteins as vaccine
candidates is based on their recognition by antibodies from
individuals naturally exposed to P. vivax [15,16,17,18], their
immunogenic properties in animal models [19,20,21], and
evidence of the induction of parasite growth-inhibitory specific
antibodies [11,13,22].
The importance of antibody responses during malaria infection
has long been observed, and the production of specific IgG
antibodies is required for the acquisition of clinical immunity. In
our previous studies we assessed naturally acquired humoral
immune responses against PvMSP-3a and PvMSP-9. Our first set
of data on antibody responses show that these proteins are targets
of the immune response in individuals naturally exposed to P. vivax
malaria transmission [15,16,17,18]. However, the population of
non-responders ranged from 21% for PvMSP-3a to 58.7% for
PvMSP-9.
We hypothesized that variations in antibody response could be
determined by genetic polymorphism of the Human Leukocyte
Antigens (HLA) class II genes and sought to relate the antibody
response to specific HLA alleles and haplotypes. There is
a significant body of evidence that the genes affecting the immune
response can influence the outcome of malaria infection and the
capacity to mount a humoral immune response [23,24]. HLA class
II genes were originally called immune response genes, since their
alleles are known to influence the antibody response. Exogenous as
well as endogenous peptides are presented in the context of HLA
class II molecules for recognition by CD4+ T lymphocytes. CD4+
T cell subsets produce cytokines that provide help to B cells for
antibody production [25]. In humans, MHC class II molecules are
encoded by three different loci, HLA-DR, -DQ, and -DP, which
display 70% similarity to each other. Polymorphism is a notable
feature of MHC class II genes. For HLA-DR, most variability
comes from DRB, with .700 known alleles at the population
level, whereas there are only three DRA variants. In contrast, both
chains of HLA-DQ and -DP are polymorphic. However for HLA-
DP, only a few alleles are prevalent [26].
The role played by the HLA system on the immune response to
malaria antigens has been extensively investigated given the
relevance of HLA-restricted immune responses for the develop-
ment of subunit vaccines [27,28,29]. Although defined host–
parasite interactions at the level of antigen processing and
presentation might affect the development of specific immune
responses, the available evidence indicates that HLA loci are an
important genetic determinant of the immune reactivity to
malaria. Several authors have reported an association between
HLA class II alleles and the acquisition of antibodies to B-cell
epitopes in the P. falciparum ring-infected erythrocyte surface
antigen (RESA), the P126 antigen, the glutamate-rich protein
(GLURP), the subunit vaccine candidate SPf66, and to the repeat
region of the P. vivax circumsporozoite protein (CSP)
[30,31,32,33,34,35,36,37,38].
There is an increasing focus on the development of subunit
malaria vaccines, and studies of the influence of class II alleles on
the immune response in ethnically diverse populations is important
before implementation of vaccine trials. This is particularly
relevant for P. vivax, which is the most widespread malaria
parasite, affecting populations with a high diversity of genetic
backgrounds. Therefore, in this study, we evaluated the influence
of HLA-DRB1* and -DQB1* allelic products on the frequency of
naturally acquired antibodies to P. vivax MSP-1, MSP-3a and
MSP-9 recombinant proteins.
Results
Epidemiological Characteristics of Studied Population
Our epidemiological survey, summarized in Table 1, shows that
all individuals studied were exposed to malaria infections
throughout the year. A significant proportion of studied individ-
uals reported a prior experience with P. vivax or P. falciparum
malaria when compared with individuals that could not recall
infections in the past and mentioned that they never had malaria
even though they were born in the endemic area (p,0.0001).
Among donors with a previous malaria infection(s), years of
residence in the endemic area correlated positively with the past
months since last malaria episode (Spearman’s r=0.2411,
P,0.0001, n=245). At the time of blood collection 34 individuals
were infected, 25 with P. vivax and 9 with P. falciparum (thus, 74.6%
of the infected individuals had P. vivax and 26.4% had P.
falciparum), consistent with the current local case distribution data
for these two species reported by the Brazilian Ministry of Health
[39].
HLA-DRB1 and HLA-DQB1 Allele Frequencies of Studied
Individuals
HLA-DRB1* and HLA-DQB1* typing was performed on DNA
samples of 276 individuals included in the cohort. Both the number
ofpositiveindividualsfortheHLA-DQB1*andHLA-DRB1*alleles
Table 1. Summary of the epidemiological characteristics of
studied individuals enrolled in this work.
Epidemiological characteristics
Gender
Male (n) 152
Female (n) 124
TOTAL (n) 276
Age (Mean 6 SD) 36.1+16.4
Time of residence in malaria endemic area (Mean 6 SD) 28.5+17.0
Number of past malaria infections (Mean 6 SD) 7.0+9.6
Number of malaria infections in the last 6 months
(Mean 6 SD)
0.5+1.1
Past months since the last malaria infection (Mean 6 SD) 41.0+50.1
Hospitalization in malaria past infections
b (n/%) 56/19.8%
Use of prophylactic measures
e 131/46.5%
Previous malaria species contracted
c
Negative (n) 31/11.3%
P. vivax (n) 56/20,2%
P.falciparum (n) 34/12.3%
Both species (n) 155/56.2%
aDifferences in gender proportions were not statistically significant (x
2=1.7281;
P=0.3447).
bWe could not determine if clinical criteria were compatible with severe malaria,
c11 (3.2%) individuals did not remember the previous malaria parasite species
contracted.
dBold typeface indicates that the prevalence was significantly higher when
compared with all other observations (P,0.0001).
eWere considered as prophylactic measure; i.e., the use of residual insecticide,
bednets or insect repellent.
doi:10.1371/journal.pone.0036419.t001
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1b. We found 13 HLA-DRB1* and 5 HLA-DQB1* allelic groups.
There were two predominant HLA allelic groups in our studied
population, HLA-DRB1*04 (16%) of all HLA-DR genotypes, and
HLA-DQB1*03 (38%) of all HLA-DQ genotypes. The HLA-
DRB1*09, HLA-DRB1*10 and HLA-DRB1*12 were less frequent
inHLA-DRB1*andHLA-DQB1*04inHLA-DQB1*.Asobserved
in Figure 1c, HLA-DRB1*04 carrier individuals also show a large
varietyofalleles,withamarkedpredominanceofHLA-DRB1*0411
(28%) over the others (P,0.05).
Frequency of IgG Response to PvMSP-1, PvMSP-3a and
PvMSP-9 and Associations with HLA-DRB1* and HLA-
DQB1* Alleles
The prevalence of naturally acquired antibodies specific to the
recombinant proteins was determined in plasma of 276 studied
individuals (Figure 2). The frequency of responders show that IgG
antibody reactivity to PvMSP119 was 86.7% and the frequency of
positive individuals for at least one of the recombinant proteins
representing PvMSP-3a and PvMSP-9 sequences was 77% and
76%, respectively. The recombinant protein representing
PvMSP119 was the most recognized of the proteins tested. A
substantial variation in terms of recognition was observed for the
different regions of PvMSP-3a. The two blocks of repeats
(MSP3RI, 62% and MSP3RII, 53%) and the C-terminal regions
(MSP3CT, 53%) were significantly more recognized (P,0.01) than
the N-terminal region (MSP3NT, 39%). Similarly, the recombinant
representing the two blocks of repeats in MSP9RIRII (63.7%) were
significantly higher when compared to the recombinant represent-
ing only the second block of repeats (MSP9RII, 40.2%; x
2=10.3;
P,0.0013) and the N terminal region (PvMSP9NT, 33.7%;
x
2=15.2; P,0.0001). Combining data from all recombinant
proteins a proportion of the population appears to be non-
responders for PvMSP-1 (13%), PvMSP-3a (22.4%) and PvMSP-9
(28.7%) and five individuals were non-responders for all
recombinant proteins.
The influence of HLA-DRB1* and HLA-DQB1* alleles and
haplotypes on the naturally acquired IgG response to the
recombinant proteins representing PvMSP-1, PvMSP-3a and
PvMSP-9 was also evaluated (Tables 2 and 3). Although 13% of
the population did not present detectable titers of antibodies to
PvMSP-1 (MSP119), genetic restriction to this antigen does not
seem to occur, since no association was observed between the
HLA DRB1* or DQB1 alleles and the antibody response to
MSP119. However for the PvMSP-3a and PvMSP-9 recombinants
proteins, the IgG responders were associated with the presence of
the HLA-DRB1*04 allelic group. The associations were found in
IgG responders to the recombinants proteins representing the C-
terminal and N-terminal regions of PvMSP-3a (MSP3CT,
P,0.025; MSP3NT P,0.025) and the two blocks of repeats and
the N-terminal region of PvMSP-9 (MSP9RIRII,P ,0.05;
MSP9RII,P ,0.05; MSP9NT,P ,0.025). Among the individuals
presenting the HLA-DRB1*04 allelic group the frequency of
responders to all recombinant proteins was higher in the HLA-
DRB1*0411 allele carriers. However, the association was not
statistically significant with any specific HLA-DRB1*04 allele
(figure 3).
The high frequency of non-responders to the recombinant
proteins representing the blocks of repeats of PvMSP-9
(MSP9RIRII and MSP9RII) is associated with the presence of the
HLA-DRB1*01 allelic group (P,0.001 and P,0.005 respectively)
and the recombinant protein representing the full length of
PvMSP-3a with the presence of the HLA-DRB1*16 allelic group
(MSP3FL)( P ,0.05). Interestingly, this association was not detected
when we evaluated the response to the recombinant proteins
representing the different regions of PvMSP3.
In the evaluation of the HLA-DQB1* allelic groups we observed
an association between HLA-DQB1*03 and responders to the
recombinant protein representing the repeats and the N-terminal
region of PvMSP-9 (MSP9RIRII P,0.05; MSP9NT P,0.05) and
the C-terminal region of PvMSP-3a (MSP3CT,P ,0.01). In
contrast, a negative association was observed between HLA-
DQB1*06 and responders to the C-terminus of PvMSP-3a
(MSP3CT,P ,0.025). All HLA associations with specific antibodies
against PvMSP-1, PvMSP-3 and PvMSP-9 are summarized in
table 4.
Effect of HLA and TREA, PMI and TLI on Antibody Levels
to PvMSP-1, PvMSP-3a and PvMSP-9
The effects of different HLA-DRB1 and HLA-DQB1 allelic
groups and time of residence (years) in malaria endemic areas on
the level of antibodies to PvMSP-1, PvMSP-3a and PvMSP-9,
were also analyzed. The DRB1 and DQB1 alleles that are
observed frequently in the population were included in these
Figure 1. HLA allele frequencies in individuals naturally exposed to malaria from the Rondonia state. HLA-DQB1* (a) and HLA-DRB1* (b)
allele frequencies (%) in 276 individuals naturally exposed to malaria from the Rondonia state enrolled in our study. HLA-DQB1*03 and HLA-DRB1*04
present significantly higher frequencies when compared with all other groups observed (P,0,05 and P,0,01 respectively). Others: DRB1*09,
DRB1*10, DRB1*12. The high resolution allele frequency distribution among the 91 HLA-DRB1*04 carriers from our studied area (c) also show a large
variety of alleles, with a marked predominance of HLA-DRB1*04:11 (28%) over the others (P,0.05).
doi:10.1371/journal.pone.0036419.g001
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(years) of residence in endemic area (TREA), time (months) since
the last malaria episode (TLI) and past malaria infections (PMI)
and DRB1 or DQB1 alleles as independent variables and the
reactivity indexes of IgG against all studied recombinant proteins
as dependent variables. A significant association was observed only
between HLA-DR+TREA and the reactivity index of IgG against
PvMSP9-RIRII (F=1.274, P=0.0333) and PvMSP9-RII
Figure 2. Frequency of IgG responders to PvMSP-1, PvMSP-3 and PvMSP-9. Frequency of IgG responders to five recombinant proteins
representing different regions of PvMSP-3a, three recombinant proteins representing PvMSP-9 and PvMSP-119 in the studied population. Chi squared
test for proportions analyses were performed to determine statistical differences. # The frequency of IgG responders to PvMSP3-FL was significantly
higher when compared with all others PvMSP-3a recombinants (P,0.05) * The frequency to PvMSP3-NT was the lowest when compared with all
others (P,0.01), and the frequencies to PvMSP9-RIRII were higher (P,0,01) when compared with other PvMSP-9 recombinants.
doi:10.1371/journal.pone.0036419.g002
Figure 3. Frequency (%) of responders to PvMSP9 and PvMSP-3 recombinant proteins by HLA-DRB1*04 alleles. Frequency (%) of
responders to PvMSP9 and PvMSP-3 recombinant proteins by HLA-DRB1*04 alleles. The frequencies of responders were not associated to a particular
HLA-DRB1*04 allelic group by the bipartition x
2 test (p.0.05). * ‘‘Others’’ category groups individuals with HLA-DRB1*04 less frequent alleles.
doi:10.1371/journal.pone.0036419.g003
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observed power of association of each independent variable
separately was greater in TREA (0.097 to 1.000) than in the HLA
allelic groups (0.345 to 0.643). Therefore, the time of exposure is
more closely related to the PvMSP-9 antibody levels. In addition
the observed power of association was similar between both
variables. No significant associations, positive or negative, were
observed with HLA-DR+TREA, HLA-DR+PMI, HLA-DR+TLI
and antibody levels to PvMSP-3a and PvMSP-1. No significant
associations were observed for any HLA-DQ+TREA, HLA-
DQ+PMI, HLA-DQ+TLI and PvMSP-1, PvMSP-3a and
PvMSP-9 antibody levels.
HLA-DRB1*04 Carriers Presented Higher Levels
of Antibodies to PvMSP-9 but not to PvMSP-1
and PvMSP-3a
Since the DRB1*04 allelic group was associated with respon-
ders, we also evaluated if the levels of antibodies, represented by
the reactivity indexes to the recombinant proteins in the ELISA
test, had the influence of these alleles. Comparing the antibody
response in carriers and non-carriers of the HLA-DRB1*04 alleles,
the levels were significantly higher in HLA-DRB1*04 carriers for
the recombinant proteins representing PvMSP-9: MSP9RIRII
(carriers Mean 6 SD=3.2360.60 vs non-carriers Mean 6
SD=1.9560.47; df=254, t=2.934, P=0.0037), MSP9RII (car-
riers Mean 6 SD=2.4960.41 vs non-carriers Mean 6
SD=1.4160.23; df=188, t=2.923, P=0.0045) and PvMSP9NT
(carriers Mean 6 SD=2.0160.29 vs non-carriers Mean 6
SD=1.3760.19; df=124, t=5.975, P,0.0001). However we
did not find any difference in the levels of antibodies between these
groups for the PvMSP-1 and PvMSP-3a responders. The antibody
levels in individuals homozygous for the HLA-DRB1*04 allelic
group did not differ from individuals that carry only one DRB1*04
Table 3. Frequency (F) and number (n) of IgG responders and non-responders to the PvMSP-9 and PvMSP-1 recombinant proteins
tested by HLA-DRB1* and HLA-DQB1*allelic groups from malaria naturally exposed individuals.
HLA MSP9-RIRII MSP9-RII MSP9-NT MSP1
Responder Non-responder Responder Non-responder Responder Non-responder Responder Non-responder
f (n) f (n) f (n) f (n) f (n) f (n) f (n) f (n)
HLA-DRB1*
DRB01 0.065 (23) 0.160 (32) 0.063 (14) 0.124 (41) 0.086 (16) 0.107 (39) 0.090 (43) 0.151(11)
DRB03 0.074 (26) 0.085 (17) 0.086 (19) 0.073 (24) 0.075 (14) 0.079 (29) 0.079(38) 0.068 (5)
DRB04 0.190 (67) 0.120 (24) 0.203 (45) 0.139 (46) 0.231 (43) 0.132 (48) 0.159 (76) 0.205 (15)
DRB07 0.097 (34) 0.120 (24) 0.131 (29) 0.088 (29) 0.108 (20) 0.104 (38) 0.106 (51) 0.123 (9)
DRB08 0.097 (34) 0.065 (13) 0.095 (21) 0.079 (26) 0.081 (15) 0.088 (32) 0.088 (42) 0.082 (6)
DRB09 0.011 (4) 0.020 (4) 0.014 (3) 0.015 (5) 0.022 (4) 0.011 (4) 0.015 (7) 0.041 (3)
DRB10 0.009 (3) 0.015 (3) 0.0 (0) 0.018 (6) 0.005 (1) 0.014 (5) 0.013 (6) 0.0(0)
DRB11 0.116 (41) 0.060 (12) 0.077 (17) 0.109 (36) 0.091 (17) 0.099 (36) 0.096 (46) 0.055 (4)
DRB12 0.009 (3) 0.005 (1) 0.009 (2) 0.006 (2) 0.0 (0) 0.008 (3) 0.006 (3) 0.014 (1)
DRB13 0.102 (36) 0.110 (22) 0.104 (23) 0.106 (35) 0.086 (16) 0.115 (42) 0.111 (53) 0.082 (6)
DRB14 0.065 (23) 0.100 (20) 0.072 (16) 0.082 (27) 0.075 (14) 0.079 (29) 0.084 (40) 0.027 (2)
DRB15 0.082 (29) 0.075 (15) 0.072 (16) 0.085 (28) 0.075 (14) 0.082 (30) 0.075 (36) 0.096 (7)
DRB16 0.082 (29) 0.065 (13) 0.077 (17) 0.076 (25) 0.065 (12) 0.082(30) 0.079 (38) 0.055 (4)
HLA-DQB1*
DQB02 0.134 (47) 0.165 (33) 0.179 (40) 0.121 (40) 0.124 (23) 0.155 (57) 0.143 (68) 0.154 (12)
DQB03 0.432 (152) 0.315 (63) 0.424 (95) 0.364 (120) 0.473 (88) 0.345 (127) 0.399(190) 0.321 (25)
DQB04 0.131 (46) 0.080 (16) 0.129 (29) 0.100 (33) 0.129 (24) 0.103 (38) 0.109 (52) 0.128 (10)
DQB05 0.139 (49) 0.235 (47) 0.125 (28) 0.206 (68) 0.140 (26) 0.190 (70) 0.168 (80) 0.205 (16)
DQB06 0.165 (58) 0.205 (41) 0.143 (30) 0.209 (69) 0.134 (23) 0.207 (76) 0.181 (86) 0.192 (15)
Bold typeface indicates the frequency of IgG responses were associated to the particular HLA-DRB1* or HLA-DQB1* allelic group by the bipartition x
2 test (P,0.05).
Each studied individual contributed two HLA allele observations to this descriptive analysis.
doi:10.1371/journal.pone.0036419.t003
Table 4. Summary of associations between HLA-DRB1* allelic
groups and the frequency of responders to PvMSP-1, PvMSP-
3a and PvMSP-9 calculated by the bi-partition X
2 test.
Protein HLA Associations P
PvMSP3-NT DRB1*04 (+) ,0.025
PvMSP3-CT DRB1*04 (+) ,0.025
DQB1*03 (+) ,0.01
DQB1*06 (2) ,0.025
PvMSP3-FL DRB1*16 (2) ,0.05
PvMSP9-RIRII DRB1*01 (2) ,0.001
DRB1*04 (+) ,0.05
PvMSP9-RII DRB1*01 (2) ,0.005
DRB1*04 (+) ,0.05
PvMSP9-NT DRB1*04 (+) ,0.025
doi:10.1371/journal.pone.0036419.t004
HLA Influence on Antibodies to P. vivax Proteins
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36419allelic group (heterozygous) independent of the recombinant
protein recognized. Finally, no relationship between a particular
HLA haplotype and the frequency of antibody response was
observed.
Discussion
Many factors can contribute to the heterogeneity of the immune
response to vaccines, including polymorphism of immune response
genes. Understanding the genetic restriction that influences the
generation of protective immune responses to Plasmodium target
proteins is important to develop novel vaccines and improve our
knowledge about current vaccine candidates. Not only bio-
chemical and structural studies of class II MHC molecules, but
also studies in specific immune responses to recombinant proteins
or synthetic peptides, provide a conceptual foundation for the
rational design of subunit vaccines.
In our study, differences in the frequency of antibodies to three
merozoite surface proteins were defined in a population similarly
exposed to malaria infections. The proportion of non-responders
varied from 13% for PvMSP-1 to 28.7% for PvMSP-9. Five
individuals were non-responders for all recombinant proteins
tested here. Differences in malaria morbidity and antibody
responses to several Plasmodium antigens suggest genetic regulation
of the immune responses [23,24]. We hypothesized that differ-
ences in the malaria antibody response to merozoite antigens
could be explained by the genetic polymorphism of the HLA Class
II alleles. However, repeated sequences, common in Plasmodium
proteins, are immunodominant [36,40,41]. Similarly, sequence
variation in allelic forms may prevent the development of cross-
reactive antibodies [42,43].
The studied population was heterogeneous presenting 13 HLA-
DRB1* and 5 DQB1* allelic groups. As expected, the Brazilian
populations have features of a tri-hybrid admixed population with
contribution from Caucasian, African, and native Amerindian
ancestors, in which the phenotypic characteristics of each original
population have been highly mixed. However, we also observed
a high frequency of HLA-DRB1*04 and HLA-DQB1*03,
suggesting that in this population the Amerindian HLA genotype
is conserved [44]. The enrollment of populations with high HLA
polymorphism but with a related degree of conservation was ideal
to observe the association of HLA allelic groups and the immune
response to P. vivax antigens.
The analysis of the presence of HLA-DRB1* and HLA-DQB1*
allelic groups and the antibody response to PvMSP119 did not
show any positive or negative association. Previous studies with P.
falciparum MSP119 also showed no association between the levels of
antibodies to one MSP119 variant and the HLA-DRB1*, DQB1*
alleles or HLA-DR/DQ haplotype [30]. Therefore, our findings
indicate that this region of PvMSP-1 is highly immunogenic in
naturally exposed populations and the acquired immune response
observed is not restricted to a particular HLA genotype [45].
Nevertheless, we showed HLA associations with the IgG immune
response to the recombinant proteins representing different
regions of PvMSP-3a and PvMSP-9. A high frequency of
responders to PvMSP3CT and PvMSP3NT were defined in HLA-
DRB1*04 carriers and to PvMSP3CT in HLA-DQB1*03 carriers.
In addition, HLA-DRB1*04 and DQB1*03 were also positively
associated with the IgG response against the N-terminal and
repetitive regions of PvMSP-9.
An association with specific IgG antibodies and HLA alleles has
been reported for some P. falciparum vaccine candidates. In malaria
patients, HLA-DRB1*07 alleles were correlated with improved
antibody responses against both domains of the chimeric protein
PfCP-2.9 (P. falciparum apical membrane antigen-1, PfAMA-1, and
PfMSP-119) but HLA-DRB1*08 had the contrary effect on
PfAMA-1 and PfMSP-119 [46]. A study in Cameroon Republic
indicated that individuals with HLA-DRB1*1201 alleles had
higher antibody responses to the recombinant PfAMA-1 variant,
but there was no association between HLA-II alleles and PfMSP-
119 antibody levels [30]. In contrast, there are few studies
reporting an HLA influence in IgG immune responses to P. vivax
proteins, however associations were observed between antibody
responses to the CSP repeats of VK247 and the presence of HLA-
DRB1*16 and HLA-DRB1*07 and the lack of antibody responses
to the CSP repeats of VK210 [29].
In this study, the highest response was associated with HLA-
DRB1*04, the most frequent alleles found in the studied
population and, coincidently, also the most frequent allele in
native individuals from the Amazon [47]. However, this popula-
tion had more time of exposure to malaria infections than the
migrants from non-endemic areas. We also observed that the time
of residence in malaria endemic areas was directly correlated with
the IgG specific immune response to PvMSP-9 but not with
PvMSP-1 and PvMSP-3a. Interestingly, the multivariate analysis
allowed us to detect the influence of both, HLA and time of
residence in a malaria endemic area (HLA+TREA) on levels of
specific antibodies to PvMSP-3a and PvMSP-9. The lack of
association in the interaction of HLA*TREA with the antibody
levels to PvMSP-3a in our study was expected, since our previous
studies demonstrated that naturally acquired antibodies raised
against PvMSP-3a are not directly associated with the time of
exposure in Brazilian endemic areas. Therefore the association
observed was mainly with HLA-DRB1*04 and HLA-DQB1*03,
suggesting that these alleles in fact could be predictors of higher
antibody levels to PvMSP-3CT and PvMSP-3NT. Conversely, we
observed an association of these interactions (TREA*HLA) and
specific IgG antibodies against the repetitive regions of PvMSP-9,
suggesting that time of residence in the endemic areas investigated
influences the antibody response rather than the HLA-DRB1*
alleles.
Although the above association exists, the extensive poly-
morphism of HLA alleles is generally accepted to have evolved as
a result of selective pressure caused by pathogens with certain
HLA types [48]. If the above associations between HLA and
antibodies to PvMSP-3a and PvMSP-9 can be associated with
protective immunity, as largely observed with IgG antibodies
against the P. falciparum MSP-3 protein [49,50,51,52], then the
higher antibody levels observed in HLA-DRB1*04 and HLA-
DQB1*03 carriers could be the result of several centuries of P.
vivax selective pressure on populations from the Amazon region
(Amerindians). Similarly, we also observe negative associations
with HLA-DQB1*06 and the IgG response against PvMSP3CT
and DRB1*01 and the repetitive regions of PvMSP-9, alleles that
are present in high frequency in Caucasian populations [47] that
historically had less selective pressure caused by P. vivax. Despite
the complex evolution of the HLA system and the difficulty posed
to disentangle the effects of molecular mechanisms such as
selection, gene conversion and recombination, we could not
exclude the strong potential influence of demographic factors and
past human migrations on the observed polymorphism. Amerin-
dian, Oceanian and Taiwanese aboriginal populations usually
exhibit few alleles at high frequencies and a small number of less
frequent ones, probably as a consequence of rapid genetic drift
[53]. Indeed, the HLA alleles found in our studied population
(Amerindians) does not represent all possible haplotypes and the
association found here could reflect the linkage disequilibrium in
the HLA allele. In addition other unidentified risk variants are also
HLA Influence on Antibodies to P. vivax Proteins
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different malaria endemic regions of Southeast Asia and Africa are
necessary to give support to the HLA-DRB1*04 allele association
with antibody responses.
We also have in mind that PvMSP-3a is highly polymorphic
and recently Ribeiro et al. [54] identify 11 haplotypes among 52
field isolates in the Brazilian Amazon and Type A was the most
prevalent in four different regions (States: Amazonas, Mato
Grosso, Amapa ´ and Para). Although the recombinant proteins
were derived from type A Belem strain it is possible that different
haplotypes circulate in Rondonia and prevent antibody recogni-
tion of recombinants proteins. Therefore, works are in progress to
evaluate the genetic background of the P. vivax strains circulating
in the studied area. On the other hand, there is also evidences that
naturally exposed individuals develop cross-reactive antibodies
which recognize an increasingly broad array of P. falciparum
isolates with increasing age or exposure [55] and in P. vivax AMA-
1 patients harbouring polymorphic haplotypes clearly demon-
strated a strain-transcending (cross reactive) antibody response
against synthetic peptides [56].
In conclusion, results of this study provide valuable information
concerning P. vivax vaccine candidates based on Merozoite
Surface Proteins. First, recombinant proteins studied here are
broadly immunogenic in a naturally exposed population. More-
over, there was no evidence of a specific HLA-DR or HLA-DQ
restriction for the antibody response to the PvMSP119. Contrast-
ingly, responders to PvMSP-3a and PvMSP-9 were associated
with the presence of HLA-DRB1*04 and HLA-DQB1*03 allelic
groups. Interestingly, HLA alleles commonly found in South
America and Southeast Asia, regions with the highest proportion
of P. vivax malaria, were associated with high frequency of
antibody responses to five out of nine proteins tested. These
features could increase the success rate of future clinical trials
based on these vaccine candidates.
Materials and Methods
Study Area and Volunteers
A cross-sectional cohort study was conducted involving 276
individuals (11 to 89 years of age) from communities in the malaria
endemic region of Rondo ˆnia state, Brazil, where P. vivax malaria
accounts for more than 70% of all malaria cases in the last five
years [57]. The individuals in the study population have been
described elsewhere [16,58]. Briefly, they consist of rain forest
natives as well as migrants from several non-endemic areas of
Brazil who have resided in the region for 10 years or more.
Samples and survey data were collected in 2007, during the dry
months of June-August, coinciding with the period of increased
malaria transmission in Rondonia State. Samples from 24 malaria
naive individuals living in non-endemic regions and who had
never visited malaria transmission zones were obtained from
laboratory staff volunteers (Rio de Janeiro, Brazil and Atlanta,
USA) and used as controls. Written informed consent was
obtained from all adult donors or from parents of donors in the
case of minors. The study was reviewed and approved by the
Fundac ¸a ˜o Oswaldo Cruz Ethical Committee and the National
Ethical Committee of Brazil.
Epidemiological Survey
To evaluate epidemiological factors that may influence the
immune response against the recombinant proteins, all donors
were interviewed upon informed consent. The survey included
questions related to demographics, time of residence in the
endemic area, personal and family histories of malaria, use of
malaria prophylaxis, presence of malaria symptoms, and personal
knowledge of malaria. Survey data was entered into a database
created with Epi Info 2007 (Centers for Disease Control and
Prevention, Atlanta, GA).
Collection of Human Blood Samples and Malaria
Diagnosis
Venous peripheral blood (20 ml) was collected into EDTA
tubes, and peripheral blood mononuclear cells (PBMC) were
isolated by Ficoll/Hypaque (Pharmacia, Piscataway, NJ) density
gradient centrifugation. Plasma was stored at –20uC and thin and
thick blood smears of all donors were examined for malaria
parasites at 10006 magnification under oil-immersion, all slides
were examined by two researchers with expertise in malaria
diagnosis. Donors positive for P. vivax and/or P. falciparum at the
time of blood collection were subsequently treated per the
chemotherapeutic regimen recommended by the Brazilian Min-
istry of Health.
HLA Genotyping of PBMC
Genomic DNA was isolated from whole blood drawn in EDTA
by using a mixture of 5 ml buffer G2 (QIAamp DNA Blood Midi
Kit; Qiagen Inc., Chatsworth, CA, USA) and 95 ml proteinase K
(20 mg/ml). After incubation at 50uC for 1 h the DNA was
ethanol precipitated, collected with a glass stick and transferred
into distilled water. DNA concentration and quality was checked
with a NanoDrop ND-1000 spectrometer (Thermo Fisher
Scientific Inc., Waltham, MA, USA). Sequence-specific oligonu-
cleotide probes (SSOPs) were used by Luminex Xmap technology
in order to determine the HLA class II allelic groups of studied
individuals. Briefly, the system is based on probe arrays bound to
color-coded plastic microspheres, and locus-specific biotinylated
primers for HLA-DRB1 and HLA-DQB1 loci (LABType, One
Lambda Inc, Canoga Park, CA, USA). Biotinylated amplicons
were denatured to ssDNA and incubated with DNA complemen-
tary probes immobilized on fluorescent coded microspheres
(beads) followed by incubation with R-Phycoerythrin conjugated
to streptavidin. After hybridization, the samples were analyzed
with Luminex Flow Analysis equipment. The HLA Visual 2.0
software (One Lambda, CA) analysis program deduces the HLA-
DRB1 and HLA-DQB1 allelic groups. High resolution PCR-SSP
typing was also used with the same method to define the DRB1*04
alleles, as these loci have been associated with responders to
malaria antigens.
Recombinant Proteins
The expression and purification of the recombinants proteins
were performed as previously described [16,58,59]. Nine recom-
binant proteins derived from P. vivax (Belem strain) were produced.
These include PvMSP-1 sequence representing the 19 kDa C-
terminal fragment (MSP119), PvMSP-3a sequence representing
the near full length protein (MSP3FL), the N-terminal region
(MSP3NT), the first block of repeats (MSP3RI), the second block of
repeats (MSP3RII), and the C-terminal region (MSP3CT), and
PvMSP-9 sequence representing the N-terminal domain
(MSP9NT), the second block of tandem repeats (MSP9R1I) and
the first and second block of tandem repeats MSP9RI-RII.
Antibody Assays
Plasma samples from study participants were screened for the
presence of naturally acquired antibodies against the nine
recombinant proteins: PvMSP-3a (MSP3FL, MSP3RI, MSP3RII,
MSP3CT, MSP3NT); PvMSP-9 (MSP9RIRII, MSP9RII, MSP9NT)
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plates (Nunc, Rochester, NY) were coated with PBS containing
2 mg per ml of each recombinant protein. After overnight
incubation at 4uC the plates were washed with PBS containing
0.05% Tween 20 (PBS-Tween) and blocked with PBS-Tween
containing 5% non-fat dry milk (PBS-Tween-M) for 2 h at 37uC.
Individual plasma samples diluted 1:100 PBS-Tween-M were
added in duplicate wells and the plates incubated at room
temperature for 1 h. After four washes with PBS-Tween, bound
antibodies were detected with peroxidase-conjugated goat anti-
human IgG (Sigma, St Louis) followed by o-Phenylenediamine
and hydrogen peroxide. The absorbance was read at 492 nm
using an ELISA reader (Spectramax 250, Molecular Devices,
Sunnyvale, CA). The results for total IgG were expressed as
Reactivity Indexes (RI), which were calculated by dividing the
mean optical density of tested samples by the mean optical density
plus 3 standard deviations of 24 non-exposed control individuals
living in non-endemic areas of malaria (OD values higher than
0.089 to PvMSP1; 0,094 to PvMSP-9RIRII; 0,091 to PvMSP9RII;
0,074 to PvMSP9NT; 0,101 to PvMSP3FL; 0,081 to PvMSP3BLI;
0,092 to PvMSP3CT; 0,091 to PvMSP3NT). As positive controls
we used five plasmas from exposed native individuals that
presented high OD levels for all three proteins. Subjects were
scored as positive to the corresponding antigen if the RI was
higher than 1.
Statistical Analysis
Survey data was recorded and entered into a database created
with Epi Info 2007 (Centers for Disease Control and Prevention,
Atlanta, GA). Analyses were done using Predictive Analytics
Software, PASW (version 17.0; SPSS Inc., Chicago, IL, USA) and
Prism version 5 (GraphPad Software Inc., San Diego, CA).
Differences in medians of past malaria infections and time since
the last infection for the study population data were tested by non-
parametric Mann-Whitney. Student’s t test was used to compare
means of normally distributed data of reactivity indexes of IgG
antibodies. Differences in gender proportions were evaluated by
chi-square (X
2) test. Allelic groups were grouped by DR status and
data were descriptively summarized using frequencies and
percentages for all categorical variables. Overall associations of
immunologic responses with the alleles from each HLA-DRB1*
and HLA-DQB1* loci were evaluated by comparing the allele
frequencies between seronegative subjects and seropositive subjects
using standard contingency tables. For a locus with K alleles,
a2 6K table was constructed by computing allele counts for each
of the two groups. Each person contributed two observations to
the table (one for each allele). Rare alleles, defined as those with
less than five occurrences among subjects, were all pooled into
a category labeled ‘‘other’’ for analysis. To evaluate global
differences in allele distribution, we performed analyses using
simulation methods as implemented in the software PASW. This
approach randomly generates new cell counts for contingency
tables under the null hypothesis of no association, while keeping
the margins of the table fixed. We used an approach that
compares each allele versus all others combined, resulting in
multiple 262 tables, and used the maximum Chi-square statistic
from this series of tables as a global test statistic (bipartition). All
global tests assume that the two alleles from each subject are
independent. Following the global tests of association, we
examined individual allele effects on seropositivity using un-
conditional logistic regression analysis. Regression variables were
created for each allele and coded as 0, 1, or 2, according to the
number of copies a subject carries. Each allele variable was first
included in a separate univariate logistic regression analysis to
determine its association with seronegativity, ignoring the effects of
other alleles. Next, to verify the influence of haplotypes,
multivariate analyses were run that examined the simultaneous
effects of multiple alleles at a given locus with seronegativity.
Separate models were fit for each of the five loci. The low
frequency of many alleles, coupled with data dependency issues,
made it impossible to fit all allele count variables from one locus in
a single logistic model. Because of this, we used a forward stepwise
regression method to choose alleles most associated with antibody
response. The significance level for entering an allele variable in
the model was 0.05. Variables not included in the final stepwise
model were, by default, pooled into a group against which the
significant allele variables were compared. To examine the
possibility of multiple effects on antibody levels, multivariate
regression analysis was also performed by Generalized Linear
Models (GLM). The reactivity index of IgG antibodies values were
used as dependent continuous variable, HLA alleles as in-
dependent variable and time (years) of residence in endemic area
(TREA), time (months) since the last malaria episode (TLI) and
past malaria infections (PMI) individually as independent
covariates. Interaction terms were also included (TREA+HLA;
TREA+TLI; TREA+PMI) to test whether the associations
between the reactivity index and HLA-DRB1* or HLA-DQB1*
were significant. Partial g
2 (Partial eta-squared) were also used to
evaluate the power of association of each variable individually in
the model. All variables included in the final locus-specific stepwise
models were placed into one overall stepwise model. As before, the
significance level for entering a variable in the model was 0.05. All
statistical tests were two sided and, unless otherwise specified, HLA
analyses were conducted using the PASW software system.
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